Soluble Botulinum Toxin Light Chain via C-Terminal Truncation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The study of botulinum neurotoxins is hindered by the intrinsic toxicity of holotoxins, limited genetic manipulation tools for Clostridia, and the need to activate the toxin, which introduces analysis errors, and recombinant botulinum toxin light chains have faced issues with solubility and stability during expression in E. coli.
Innovation Solution
A preparation of catalytically active and soluble botulinum toxin light chain type A or E is developed by expressing specific DNA sequences encoding amino acid residues 1-425 or 1-408, which are then purified and used for inhibitor screening and antibody production, enhancing solubility and stability through C-terminal deletions and optimized expression and purification methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If botulinum toxin holotoxin is used for study, then catalytic activity can be obtained, but intrinsic toxicity and the need for activation introduce errors and limitations
Solution Approach 1:
The botulinum toxin holotoxin is divided into two separate chains: the heavy chain (HC) responsible for binding and translocation, and the light chain (LC) responsible for catalytic activity. By expressing and purifying only the LC portion (residues 1-425 of BoNT/A or 1-408 of BoNT/E), the invention eliminates the toxic holotoxin while retaining the catalytic function for reliable studies.
Solution Approach 2:
The catalytic light chain is extracted and isolated from the toxic holotoxin structure. The invention expresses the LC as a standalone recombinant protein in E. coli, removing the harmful heavy chain components while preserving the essential proteolytic activity for substrate cleavage.
2Quantity of substance
If full-length botulinum toxin light chain is expressed in E. coli, then complete sequence is obtained, but solubility and stability are compromised
Solution Approach 1:
The C-terminal region (residues 426-448 of BoNT/A or 409-438 of BoNT/E) is removed from the light chain sequence. This deletion eliminates the problematic hydrophobic C-terminal tail that causes aggregation and insolubility in E. coli, while preserving the essential catalytic domain and N-terminal regions.
Solution Approach 2:
The invention modifies only the C-terminal region of the light chain while maintaining the integrity of the catalytic core and other functional domains. This localized truncation improves solubility and stability without compromising the essential proteolytic activity on SNARE proteins.
3Stability of the object's composition
If C-terminal deletions are made to improve solubility, then expression and solubility are enhanced, but complete sequence is not obtained
Solution Approach 1:
The invention changes the sequence length parameter by truncating the C-terminus to 425 or 408 residues. This parameter modification optimizes the balance between solubility and catalytic function, creating a truncated but fully functional light chain suitable for structural and functional studies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting preparation allows for detailed structure-function studies, improved solubility, and stability, enabling effective screening of inhibitors and potential therapeutic applications, such as immunotherapy against botulism.
Implementation Method 1
BoNT LCs are zinc metalloproteases that cleave one of three proteins, collectively termed SNARE proteins
Data Source
AI summary
The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide.